

1     **The potential impact of delta variant of SARS-CoV-2 in the context of**  
2     **limited vaccination coverage and increasing social mixing in Bogotá,**  
3     **Colombia**

4  
5     Guido España<sup>1,#</sup>, Zulma M. Cucunubá<sup>2,3,#</sup>, Juliana Cuervo-Rojas<sup>2</sup>, Hernando Díaz<sup>4</sup>,  
6     Manuel González-Mayorga, Juan David Ramírez

7  
8     <sup>1</sup>Department of Biological Sciences and Eck Institute for Global Health, University of Notre  
9     Dame, USA

10    <sup>2</sup>Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina, Pontificia  
11    Universidad Javeriana, Bogotá, Colombia

12    <sup>3</sup>MRC Centre for Global Infectious Disease Analysis, J-IDA, Imperial College London, London,  
13    UK

14    <sup>4</sup>Departamento de Ingeniería Eléctrica y Electrónica, Universidad Nacional de Colombia,  
15    Bogotá, Colombia

16    <sup>5</sup>Sub-secretaría de Salud Pública. Secretaría Distrital de Salud de Bogotá, Bogotá, Colombia

17    <sup>6</sup>Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de  
18    Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.

19  
20    #Correspondence: [guido.espana@nd.edu](mailto:guido.espana@nd.edu), [zulma.cucunuba@javeriana.edu.co](mailto:zulma.cucunuba@javeriana.edu.co)

26 **Abstract**

27

28 **Background:** More than 122,000 COVID-19 associated deaths have been reported in Colombia  
29 and about 27,000 in the city of Bogotá by the first week of August, with vaccination coverage in  
30 the city at 30% for complete schemes and at 37% for partial vaccination. As the incidence of  
31 cases currently decreases, questions remain about the potential impact of the delta variant already  
32 present in the city.

33 **Methods:** We used an agent-based model calibrated to data on age-structured deaths and  
34 dominance of variants in Bogotá. We used efficacy data for the portfolio of vaccines available,  
35 including known changes for SARS-CoV-2 variants. We modelled scenarios of early and  
36 delayed introduction of the delta variant in the city along with changes in mobility and social  
37 contact, and vaccine strategies over the next months.

38 **Findings:** We estimate that by mid July, vaccination may have already prevented 17,800 (95%  
39 CrI: 16,000 - 19,000) deaths in Bogotá. The delta variant could become dominant and lead to a  
40 fourth wave later in the year, but its timing will depend on the date of introduction, social mixing  
41 patterns, and vaccination strategy. In all scenarios, higher social mixing is associated with a  
42 fourth wave of considerable magnitude. If an early delta introduction occurred (dominance by  
43 mid July), a new wave may occur in August/September and in such case, age prioritization of  
44 vaccination and second dose not postponed are more important. However, if introduction  
45 occurred one or two months later (dominance by mid August/September) the age-prioritization is  
46 less relevant but maintaining the dose scheme without postponement is more important. In all  
47 scenarios we found that increasing the vaccination rate from the current average of 50,000/day to  
48 100,000/day reduces the impact of a fourth wave due to the delta variant.

49 **Conclusions:** In Bogotá, the delta variant could still lead to a fourth wave, whose magnitude  
50 would depend on its introduction time and the level of social mixing. Its impact can be mitigated  
51 by increasing vaccination rates to achieve high coverage quickly, with non-delayed second  
52 doses. We found that, at this point, suspending the age prioritization to achieve higher coverage  
53 with first doses does not seem to have a major effect on deaths and ICU demand. But, delaying  
54 the second dose may not be beneficial and may even increase the incidence of severe outcomes.

55

56

## 57 **Introduction**

58 In Colombia, by the beginning of August 2021, 4.8 million COVID-19 cases and 122,000 deaths  
59 due to COVID-19 had been reported [1]. Bogotá contributes to close to 30% of the cases in the  
60 country, with 1.4 million reported by the first week of August [2]. The third wave of the  
61 epidemic in the country surpassed the magnitude of the previous two, and overwhelmed the  
62 capacity of the health system.

63 Vaccination against COVID-19 initiated in the country on February 17, 2021 with various  
64 vaccines introduced progressively (CoronaVac/Sinovac, Pfizer-BioNTech BNT162b2,  
65 Oxford/AstraZeneca (AZD1222), Janssen (J&J) Ad26.COV2.S, and more recently Moderna  
66 mRNA-1273). The Ministry of Health defined a prioritization strategy that started with health  
67 care workers, and then in the general population beginning with the older age groups and those  
68 with comorbidities [3]. By the beginning of August, 32% of the total population of Colombia  
69 had received at least one dose and about 25% had a complete scheme [3,4]. In Bogotá, 5.3  
70 million doses have been administered, with 38% of the population having received at least one  
71 dose, and close to 30% a completed vaccination scheme. Under the age-prioritization strategy,  
72 the country has started to vaccinate those above 25 years [5].

73 Various SARS-CoV-2 variants have been reported in Colombia. The alpha variant (B.1.1.7) was  
74 first reported on April 16, 2021, and the gamma variant (P.1) on January 29, 2021. In addition,  
75 several regions in Colombia have reported since the beginning of January the B.1.621 variant,  
76 which then became dominant during the third wave of COVID-19 [6]. The delta variant  
77 (B.1.716.2) was reported on July 26, 2021. This VOC has overtaken as dominant in various  
78 countries in Latinamerica such as Brazil, Mexico, and Costa Rica [7]. Delta has been described  
79 in the United Kingdom as 1.5 times more transmissible than alpha, with increased severity, and  
80 able to partially escape the effect of vaccines [8,9]. Given the characteristics of delta, it is  
81 important to quantify its potential impact if it becomes the dominant variant in Bogotá.

82  
83 We used a detailed agent-based model of the epidemic in Bogotá to explore the impact of  
84 multiple circulating variants, including delta. We also studied the impact of changing social  
85 mixing patterns in the city and different vaccination strategies.

86

87 **Results**

88

89 *Model calibration until third wave*


90 The model was calibrated to daily reported deaths and seroprevalence data in Bogotá. Using  
91 preliminary data on variants dominance in the city, observed mobility, and vaccination coverage,  
92 we reproduced the daily trends of deaths, as well as the effective reproduction number and daily  
93 intensive care unit (ICU) beds demand in the city (Fig 1, Fig S4). Although the third wave has  
94 been the largest in the city, and the model shows an attack rate over 80% in the city by July, our  
95 simulations show that the vaccination program already had a large impact on the peak and total  
96 number of deaths. Up to mid July, 2021, we estimate a total of 17,800 (95% CrI: 16,000 -  
97 19,000) deaths averted by vaccination (Fig 1).

98

99 The model results suggest that the third wave of infections was caused mainly by the B.1.621  
100 followed by the gamma variant (Fig S3). We estimated that the B.1.621 variant is likely to be 1.2  
101 (1.2 -1.98) times more transmissible and able to evade immunity from previous infections at  
102 37% (19% - 48%), compared to the original lineages. We estimated the potential early  
103 introduction of the alpha variant in Bogotá to be around November 2020, followed by the  
104 introduction of gamma early in January, 2021 (Fig S2), whereas the appearance of B.1.621 may  
105 have occurred later in the month [6]. Based on this framework, our baseline scenario assumed  
106 that importations from the delta variant may have started in Bogotá since May, 2021 (Fig S2),  
107 but in such a case, delta would not become dominant before August (Fig S3). Calibrated  
108 parameters are listed in Table S1.

109

110



111  
112 **Fig 1. Model calibration and validation until third SARS-CoV-2 wave in Bogotá, Colombia.** Panel A shows the daily  
113 number of deaths in the city, panel B shows the estimated infection attack rate, panel C shows the effective reproductive number,  
114 and panel D shows the daily demand for intensive care unit beds (ICU) due to COVID-19. In all panels, black lines show the  
115 calibrated model and red color the data. The gray lines show the dynamics of an alternative scenario without vaccines.

116  
117 *Model future projections*


118 The baseline model assumes that the delta variant has already been introduced in the city but it is  
119 still not dominant. Projections show a fourth wave of COVID-19 in the city due to the delta  
120 variant, however its magnitude may depend on the date of introduction of delta, the social  
121 mixing patterns, and the vaccination coverage achieved at the time of dominance (Fig 2).

122  
123 Our model results show a magnitude of a fourth wave of COVID-19 in Bogotá would depend on  
124 the intensity of social mixing over the coming months. The current level of social mixing  
125 assumes a moderate-high level of mobility with a moderate level of contacts, while the scenario  
126 of higher social mixing assumes an increase in the number of contacts per person, in the  
127 community overall, in addition to high levels of mobility. In all scenarios, higher social mixing  
128 increased the projected number of deaths and ICU demand in the context of a dominant delta

129 variant (Fig 2). With high social mixing, an early introduction of delta would result in a peak of  
130 189 (95% CrI: 160-245) daily deaths, whereas a late introduction would cause a peak of 130  
131 (95% CrI: 116 - 180). In both scenarios of the timing of delta, reduced social mixing resulted in a  
132 smaller peak. With moderate social mixing, an early introduction of delta would result in a peak  
133 of 104 (95% CrI: 77-150) daily deaths, compared to 59 (95% CrI: 47-136) daily deaths in the  
134 scenario of late introduction of delta.

135  
136 Another driver of the potential magnitude of the fourth wave is the vaccination coverage  
137 achieved by the time delta is dominant. In scenarios of an early introduction of delta (dominance  
138 in August), our simulations showed that a new wave may occur in August/September, and in  
139 such case, changes in the vaccination strategies would have a small effect in the dynamics of the  
140 fourth wave. Nonetheless, increasing the vaccination rate to 100,000 vaccines/day could slightly  
141 reduce the impact on deaths and ICU demand if age continues to be prioritized and intervals  
142 between doses are not postponed to 84 days. Postponing the dose interval to 84 days resulted in  
143 an increased number of deaths in this scenario, even with higher vaccination rates (Fig 3 & S5,  
144 left column). In the scenario in which delta introduction occurs two months later (dominance in  
145 October), the age-prioritization for adults is less relevant but maintaining the dose scheme  
146 without postponement is more important. In this scenario, we found that increasing the  
147 vaccination rate to 100,000/day (the maximum possible according to health authorities) could  
148 have a larger impact in reducing the burden of a fourth wave due to the delta variant. These  
149 findings remain similar even if assuming that efficacy against infection is 100% of the efficacy  
150 against symptoms (Figs S6 & S7).

151



152

153 **Fig 2. Projections of potential impact of delta variant on a fourth SARS-CoV wave in Bogotá, according to timing of delta**

154 **introduction and social mixing patterns.** Columns show the timing of delta introduction, defined as early (calibrated), 30+

155 delta (delayed 30 days), and 60+ delta (delayed 60 days). Panels A-C show the daily number of deaths, panels D-F show the daily


156 demand for ICU beds, panels G-I show the cumulative number of deaths from August to November, and panels J-L show the

157 cumulative number of ICU beds in the city from August to November. Dark blue lines show a scenario of high mobility and high

158 contacts, and light blue lines indicate the current estimated levels of mobility and contacts in the city. The red lines (right axis)

159 represent the coverage of vaccination in proportion to the total population.

160



161  
 162 **Fig 3. Projections of potential impact of delta variant on a fourth SARS-CoV-2 wave in Bogotá, according to timing of**  
 163 **delta introduction, level of social mixing, and vaccination strategies.** Columns show the timing of delta introduction, defined  
 164 as early (calibrated), 30+ delta (delayed 30 days), and 60+ delta (delayed 60 days). Panels A-C show the daily number of deaths  
 165 under a scenario of high social mixing, panels D-F show the daily number of deaths under a scenario of moderate social mixing,  
 166 panels G-I show the difference in the cumulative number of deaths between alternative vaccination strategies and the baseline  
 167 scenario (50 thousand vaccines/day with age prioritization and non-postponed second dose) with high social mixing, and panels  
 168 J-L show the difference in the cumulative number of deaths between alternative vaccination strategies and the baseline scenario  
 169 (50 thousand vaccines/day with age prioritization and non-postponed second dose) with moderate social mixing. Black line  
 170 shows the baseline scenario of mobility and current vaccination strategy. Dashed lines show the impact of increasing the interval  
 171 between Pfizer vaccine doses to 84 days. Blue colors show the impact of increased vaccination rates (100,000/day) without age  
 172 priority. Green colors show the impact of increased vaccination rates (100,000/day) with age priority. Gray colors show the  
 173 impact of baseline vaccination rates without age priority.

## 174 **Discussion**

175

176 We simulated the impact of the introduction of the delta variant with an agent-based model that  
177 includes a detailed representation of the population of Bogotá by age, geographic location, and  
178 main social activities and mobility patterns (schools, universities, workplaces, long-term care  
179 facilities, households, and neighborhoods). This model has been previously validated to COVID-  
180 19 dynamics in various places [10,11]. We found that the increased number of cases and deaths  
181 during the third wave of COVID-19 in the city could be explained by a combination of higher  
182 mobility and social contacts, along with the presence of variants of concern or interest, in  
183 particular gamma may explain the first part, and B.1.621 the second part of the third wave.

184 B.1.621 may have overcome the gamma variant as dominant despite being potentially introduced  
185 at similar times. Interestingly, we found that the alpha variant was not a driver of the third wave.  
186 Despite an estimated high infection attack rate in the city, our model suggests that there is still a  
187 risk of an additional fourth wave produced by the delta variant, whose amplitude would depend  
188 on the timing of introduction of delta, the vaccination coverage and strategy, and the level of  
189 social mixing over the next months.

190

191 We evaluated the potential impact of postponing the second dose on the potential future  
192 dynamics of COVID-19 in the city. We found that in our context this may not contribute to  
193 reducing the impact of a fourth wave, in contrast to previous modeling analyses that have shown  
194 benefits at the population level [12,13]. However, those studies have been evaluated for non-  
195 delta variants. Also, the benefits of second dose postponement is still under debate [14,15].  
196 Furthermore, some studies have suggested that postponing the second dose may be related with  
197 more stronger and durable immune protection [16,17]. However, even if this holds,  
198 postponement of second dose would result in less protection at the individual level for those with  
199 incomplete vaccination scheme under the imminence of the presence of delta variant that may  
200 result in higher impact at the population level. Indeed, recent studies indicate that the  
201 effectiveness of the first dose of the Pfizer-BioNTech BNT162b2 and the Oxford/AstraZeneca  
202 (AZD1222) vaccines considerably decreases for the delta variant (being around 33%) [8].

203

204 We also evaluated the impact of different vaccination roll-out strategies. We found that even if  
205 vaccination rates are doubled, under a scenario of early introduction of delta, there might not be  
206 enough time to mitigate the impact of a fourth wave. However, if the introduction of delta is  
207 delayed or social mixing remains moderate, increasing the vaccination rates may result in a  
208 milder fourth wave. Our results suggest that in the context of a delayed presence of delta, a  
209 preferred strategy for the city is maintaining moderate levels of social mixing combined with a  
210 rapid increase in vaccination rates (even without age prioritization) and administering a second  
211 dose without postponement.

212

213 Based on vaccination coverage data available and vaccine hesitancy for adults being estimated in  
214 population-based surveys at 12,8% [18], our model assumes that about 10% of the target  
215 population remains not vaccinated, despite already being eligible. This means that for each target  
216 group of the vaccination campaign roll-out plan there is a remaining high-risk population that has  
217 not been vaccinated (due to hesitancy or access barriers). Although we did not model strategies  
218 to reach these populations, reaching these groups will have the highest impact in reducing severe  
219 disease outcomes in a future wave of COVID-19.

220

## 221 **Limitations and strengths**

222 Our model relies on data to adjust current dynamics and to project hypothetical scenarios of  
223 future transmission. Currently, there is scarce data corresponding to dominance of SARS-CoV-2  
224 variants in the city, which may affect our estimates of dominance of variants. Also, our  
225 projections rely on our ability to project future social mixing patterns, which has proved  
226 challenging. For these reasons, we have considered scenarios of moderate and high social mixing  
227 levels over the coming months. Our model also relies on available data on vaccination efficacy  
228 or effectiveness against multiple variants. However, for some of them, there is still considerable  
229 uncertainty. These include, for instance, the effectiveness of CoronaVac/Sinovac vaccine against  
230 the delta variant, and of all the vaccines against the B.1.621 variant. Moreover, our model has  
231 not considered data on waning immunity over time. Further work may also include estimates of  
232 the potential impact of boosters, particularly in high-risk populations. Also, we did not include  
233 the potential effect of milder disease in breakthrough infections and reinfections due to T-cell  
234 response.

235

## 236 **Acknowledgements**

237 We thank the University of Notre Dame Center for Research Computing for computing  
238 resources. GE received funding from an NSF RAPID grant (DEB 2027718). HD received partial  
239 funding from the National University of Colombia (Universidad Nacional de Colombia  
240 (HERMES 50419)). ZMC receives funding from the Medical Research Council  
241 (MR/R024855/1). ZMC and GE are *ad honorem* members of the Scientific Advisory Group on  
242 epidemiological modeling at Secretaría de Salud of Bogotá. MGM holds a decision-making  
243 position at Secretaría de Salud of Bogotá. We thank Charlie Whittaker from MRC-GICA at  
244 Imperial College London for his valuable input into variant characteristics and modeling.

245

246

## 247 **Methods**

### 248 *Data*

249 Time-varying trends of cases and deaths were obtained from public data sources [19]. We used  
250 the daily number of deaths reported in Bogotá as of mid-July 2021, population based  
251 seroprevalence data as of Nov, 2020 (based on anti-SARS CoV-2 IgG) [20], and available  
252 prevalence data on variants over the third wave in Bogota based on 120 samples from the  
253 epidemiological weeks 12 to 22 [21] to calibrate the model parameters. To represent changes in  
254 mobility, we used Google Mobility Reports [22] and Grandata project [23], both freely available  
255 online. Data on vaccination were obtained from datasets available online from the Ministry of  
256 Health [24](Fig S1). We obtained daily ICU bed demand from the Secretary of Health of Bogotá.  
257 Other data sources to create the synthetic population were obtained from official population  
258 projections by age for 2021[25], IPUMS-International [26] and the Secretary of Education of  
259 Bogotá.

260

### 261 *Model*

262 We extended a previous version of our SARS-CoV-2 Bogotá model [10] to include the potential  
263 effect of vaccination and variants. Our agent-based model simulates transmission of SARS-CoV-  
264 2 based on daily activity patterns of a synthetic population, representing demographic and  
265 geographic characteristics of the total population of Bogotá. Social mixing was considered in the

266 model assuming two ways to increase contacts: mobility and average number of contacts.  
267 Mobility in the model represents the proportion of people who leave their household to  
268 participate in other activities, such as school or work. Community contacts are included in the  
269 model as an average number of contacts that an individual has in the community, given that the  
270 individual leaves the household. For instance, both mobility and community contacts may  
271 increase in holidays.

272

273 We calibrated the model in a two-step fashion. First, we fitted parameters related to transmission  
274 of the original lineage of the virus by contrasting the model outputs to daily incidence of deaths  
275 reported from March 2020 to December 2021. Then, drawing from this calibrated distribution of  
276 parameters, we fitted parameters related to the transmissibility, immunity escape, and  
277 introduction of the alpha, gamma, and B.1621 variants. In this step, we calibrated the model  
278 parameters to the daily incidence of deaths and the preliminary dominance data obtained from  
279 samples for weeks 12 to 22. Finally, the model was validated against the only available  
280 population based seroprevalence study (as of Nov 2020 [20]) and daily ICU requests provided by  
281 the city's Secretary of Health. Parameters of the delta variant were assumed as the median value  
282 of estimates from other studies [27].

283

#### 284 *Variants' parameters and importation*

285 To calibrate the parameters related to transmission and immunity escape for the different  
286 variants, we used the ranges reported in the literature (Table 1). The date of introduction of  
287 variants was estimated using reported cases from international travelers and the prevalence of  
288 variants in their countries of origin [28], as well as the presence of the emerging B.1.621 variant  
289 in the country of origin [6]. Hence, the total number of imported infections from variant 'v' can  
290 be estimated as

291

$$292 N_v(t) = f_v \times N(t) \times (\sum_c D_v(c, t) * P_c),$$

293

294 where  $N(t)$  is the total imports detected in the city for time 't';  $D_v(c, t)$  is the dominance of  
295 variant 'v' in country 'c' at time 't' as reported at [21] as of June 30th, 2021;  $P_c$  is the overall

296 proportion of importations detected in the city from country ‘ $c$ ’; and  $f_v$  is a scaling factor  
297 estimated using daily deaths and dominance data from sequenced samples.

298

299 **Table 1. Parameter bounds for characteristics of variants included in the calibration.**

Variant	Transmission	Escape	Date first reported	Source
Alpha (B.1.1.7)	1.5	0.00 - 0.05	2021-03-10	[29]
Gamma (P.1)	1.7 - 2.4	0.21 - 0.46	2021-03-24	[30]
Delta (B.1.617.2)	2.10 - 2.46	0.10 - 0.55	2021-07-26	[27]
B.1621	1.0 - 2.0	0.0 - 0.5	2021-03-14	Used for estimation

300

301 *Vaccination*

302

303 *Vaccination parameters*

304 We included four vaccines currently used in Colombia, namely, Oxford/AstraZeneca  
305 (AZD1222), Pfizer-BioNTech BNT162b2, CoronaVac/Sinovac, and Janssen (J&J)  
306 Ad26.COVS.2.S. We used vaccine efficacy as reported from the clinical trials, except when the  
307 trial had not enough power to report efficacy (i.e. severe disease, death) or estimates were not  
308 available, in which case, results from observational studies were used. The point estimate and  
309 confidence intervals for the protection against symptomatic, and severe disease are listed in  
310 Table S1.

311

312 We considered that the protective effect of vaccines starts after a period that can vary between 7  
313 and 15 days after the first or second dose according to what is reported for each vaccine (Refs in  
314 Table S1). We assumed that vaccines have some level of protection against infection. Given the  
315 uncertainty in this regard, in our main analyses we assumed that protection against infection is  
316 50% of that reported for symptomatic disease. We also considered an alternative scenario of  
317 efficacy against infection being 100% of the efficacy against symptomatic disease. The arrival of  
318 each type of vaccine and the maximum number of vaccines delivered each day were determined  
319 by the vaccination delivery reports by the country’s Ministry of Health [24], as shown in Fig S1.

320 To project the future delivery of vaccines, we assumed constant availability with the proportion  
321 of vaccine types determined by the current one. In terms of the daily capacity of vaccine  
322 administration, we assumed that the current daily vaccination rates would remain until the target  
323 population is completely vaccinated. We also assume a probability of vaccine uptake of 90%.

324

### 325 *Simulation scenarios*

326 We assessed the potential impact of delta variant introduction in the city by calibrating the  
327 transmission model to current patterns and projecting the number of deaths and the demand for  
328 ICU beds, from August to November 2021. The baseline scenario used the calibrated parameters  
329 for alpha, gamma, and B.1.621. For delta, we assumed the median value of studies reported in  
330 the literature [29,30]. The scaling factor of imports of delta was assumed to be a middle point  
331 similar to values calibrated to the alpha and gamma variants.

332

333 We simulated a set of scenarios to calculate the impact of mobility and the timing of the  
334 introduction of the delta variant. To evaluate the potential impact of mobility and contacts on the  
335 future dynamics of COVID-19 due to the delta variant, we simulated two different scenarios of  
336 mobility and contacts. The baseline scenario assumed the current levels of mobility and moderate  
337 contacts. We also considered a scenario of high mobility and high contacts, which assumed that  
338 contacts increased to the levels observed during December 2020. We evaluated two additional  
339 scenarios for the timing of the introduction of the delta variant: 30 or 60 days later than our  
340 baseline estimates.

341

342 We simulated alternative scenarios of vaccination considering: the increase in the vaccination  
343 capacity to 100,000 vaccines per day, a delivery with no age-based prioritization for future  
344 administration in contrast with the current age-prioritized strategy, and the postponing of the  
345 second dose of the Pfizer BioNTech's BNT162b2 mRNA vaccine (from 21 to 84 days). We  
346 calculated the effect of these administration strategies on the cumulative number of deaths and  
347 ICU beds required from August 1st to November 1st, 2021, and the differences with the baseline  
348 scenario.

349

350

351 **Supplementary material**

352 **Table S1. Parameter values for vaccine efficacy**

Variant	Vaccine	Efficacy against Symptomatic Disease		Efficacy against Severe Disease		Ref
		One dose	Two doses	One dose	Two doses	
<b>Pre-delta variants</b>	Oxford/AstraZeneca (AZD1222)	No data	0.78 (0.68, 0.85)	No data	0.9	[31]
	CoronaVac/Sinovac	0.58 (0.46,0.67)	0.51 (0.36,0.62)	0.43 (0.37,0.48)	0.89 (0.84,0.92)	[32][33]
	Pfizer-BioNTech BNT162b2	0.71 (0.69,0.73)	0.91 (0.89,0.93)	0.8	0.9	[31] [34,35]
	Moderna mRNA-1273	0.73 (0.70,0.76)	0.94 (0.89,0.97)	0.8	0.9	[31] [36]
	Janssen (J&J) Ad26.COV2.S	0.67 (0.59,0.73)	-	0.93 (0.73,0.99)	-	[37]
	<b>Delta variant</b>	Oxford/AstraZeneca (AZD1222)	0.3 (0.24, 0.35)	0.67 (0.61,0.72)	0.71 (0.51,0.83)	0.92 (0.75-0.97)
	CoronaVac/Sinovac	0.46 (0.37-0.54)	0.41 (0.21,0.50)	0.43 (0.37,0.48)	0.89 * (0.84,0.92)	Inferred from [39] and [40]
	Pfizer-BioNTech BNT162b2	0.36 (0.23-0.46)	0.88 (0.85-0.90)	0.94 (0.46-0.99)	0.96 (0.86-0.99)	[8] [38]
	Moderna mRNA-1273	0.36 (0.23-0.46)	0.88 (0.85-0.90)	0.94 (0.46-0.99)	0.96 (0.86-0.99)	Assumed from [8] [38]

	Janssen (J&J) Ad26.COV2.S	0.60 (0.51,0.63)	-	0.93 (0.73,0.99)	-	Inferred from [39] and [40]
*Situations where there is no clinical trial and so effectiveness data was used						
** Situations where either efficacy or effectiveness data are not available and so values were inferred based on model by [39] and [40]						

353

354

355

356


357 **Table S2. Calibrated parameters.**

Parameter	Value	Source
Transmissibility	0.37	Calibrated
Alpha transmissibility compared to original	1.5	[29]
Gamma transmissibility compared to original lineages	2.0 (95% CrI: 1.1 - 2.2)	Calibrated
B.1.621 transmissibility compared to original lineages	1.23	Calibrated
delta transmissibility compared to original	2.1	Assumed
Alpha immunity escape	0.089 (95% CrI: 0.086 - 0.094)	Calibrated
Gamma immunity escape	0.27 (95% CrI: 0.26 - 0.29)	Calibrated
B.1.621	0.45 ( 95% CrI: 0.19 - 0.45)	Calibrated
Delta immunity escape	0.3	Assumed
Alpha importations scaling factor	5.9 (95% CrI: 2.9-8)	Calibrated
Gamma importations scaling factor	6 (95% CrI: 5.9 - 9.35)	Calibrated
B.1.621 Bogotá importation day	2021/01/24 (2021/01/04 - 2021/02/17)	Calibrated
Delta importations scaling factor	5	Assumed
Facemask adherence	0.71	Calibrated


358

359

360




361  
362 **Fig S1. Vaccine stock and coverage in Bogotá.** Panel A shows the arrival of vaccines by date and type of vaccine. Panel shows  
363 the coverage of fully vaccinated individuals divided by the total population of the city. Panel C shows daily vaccines  
364 administered in the model (gray) and data (red).  
365




366  
 367 **Fig S2. Importation of SARS-CoV-2 infections to Bogotá by variants and country of origin.** Panel A shows the proportion of  
 368 countries of origin from detected importations in the city of Bogotá, panel B shows a smoothed line of the trend of imports in the  
 369 city, panel C shows the baseline estimated imports for each variant in the city, and panel D shows the proportion of the imports  
 370 from each variant, according to prevalence in each country of origin.

371  
 372  
 373  
 374



375  
376 **Fig S3. Model fit to dominance of variants.** Panel A shows the dominance of different variants in the city for the scenario of  
377 early introduction of delta, panel B shows the dominance of variants for the scenario of delta 30+ (30 days delayed), and panel C  
378 shows the dominance of variants for the scenario of delta 60+(60 days delayed). Each line shows the dominance of each variant  
379 as estimated by the model. Diamonds show the data on dominance from these variants. Date of sample collection calculated as 7  
380 days after infection.

381




382


383

384

**Fig S4. Model fit to age-specific deaths.** Black lines show the model daily number of deaths, and red dots and lines show the reported daily deaths for each age group.




385  
 386 **Fig S5. Projections of potential impact on ICU beds of delta variant on a fourth SARS-CoV-2 wave in Bogotá, according to**  
 387 **timing of delta introduction, level of social mixing, and vaccination strategies.** Columns show the timing of delta introduction,  
 388 defined as early (calibrated), 30+ delta (delayed 30 days), and 60+ delta (delayed 60 days). Panels A-C show the daily number of  
 389 ICU demand under a scenario of high social mixing, panels D-F show the daily number of ICU demand under a scenario of moderate  
 390 social mixing, panels G-I show the difference in the cumulative number of ICU beds between alternative vaccination strategies and  
 391 the baseline scenario (50 thousand vaccines/day with age prioritization and non-postponed second dose) with high social mixing,  
 392 and panels J-L show the difference in the cumulative number of ICU beds between alternative vaccination strategies and the  
 393 baseline scenario (50 thousand vaccines/day with age prioritization and non-postponed second dose) with moderate social mixing.  
 394 Black line shows the baseline scenario of mobility and current vaccination strategy. Dashed lines show the impact of increasing  
 395 the interval between doses to 84 days for the Pfizer vaccine. Blue colors show the impact of increased vaccination rates  
 396 (100,000/day) without age priority. Green colors show the impact of increased vaccination rates (100,000/day) with age priority.  
 397 Gray colors show the impact of baseline vaccination rates without age priority.



398  
 399 **Fig S6. Projections of potential impact of delta variant on a fourth SARS-CoV-2 wave in Bogotá, according to timing of**  
 400 **delta introduction, level of social mixing, and vaccination strategies, under an alternative scenario of VE against infection**  
 401 **(100% of VE against symptomatic disease).** Columns show the timing of delta introduction, defined as early (calibrated), 30+  
 402 delta (delayed 30 days), and 60+ delta (delayed 60 days). Panels A-C show the daily number of deaths under a scenario of high  
 403 social mixing, panels D-F show the daily number of deaths under a scenario of moderate social mixing, panels G-I show the  
 404 difference in the cumulative number of deaths between alternative vaccination strategies and the baseline scenario (50 thousand  
 405 vaccines/day with age prioritization and non-postponed second dose) with high social mixing, and panels J-L show the difference  
 406 in the cumulative number of deaths between alternative vaccination strategies and the baseline scenario (50 thousand vaccines/day  
 407 with age prioritization and non-postponed second dose) with moderate social mixing. Black line shows the baseline scenario of  
 408 mobility and current vaccination strategy. Dashed lines show the impact of increasing the interval between doses to 84 days for the  
 409 Pfizer vaccine. Blue colors show the impact of increased vaccination rates (100,000/day) without age priority. Green colors show

410 the impact of increased vaccination rates (100,000/day) with age priority. Gray colors show the impact of baseline vaccination rates  
 411 without age priority.



412  
 413 **Fig S7. Projections of potential impact on ICU beds of delta variant on a fourth SARS-CoV-2 wave in Bogotá, according**  
 414 **to timing of delta introduction, level of social mixing, and vaccination strategies, under an alternative scenario of VE**  
 415 **against infection (100% of VE against symptoms).** Columns show the timing of delta introduction, defined as early  
 416 (calibrated), 30+ delta (delayed 30 days), and 60+ delta (delayed 60 days). Panels A-C show the daily number of ICU demand  
 417 under a scenario of high social mixing, panels D-F show the daily number of ICU demand under a scenario of moderate social  
 418 mixing, panels G-I show the difference in the cumulative number of ICU beds between alternative vaccination strategies and the  
 419 baseline scenario (50 thousand vaccines/day with age prioritization and non-postponed second dose) with high social mixing, and  
 420 panels J-L show the difference in the cumulative number of ICU beds between alternative vaccination strategies and the baseline  
 421 scenario (50 thousand vaccines/day with age prioritization and non-postponed second dose) with moderate social mixing. Black  
 422 line shows the baseline scenario of mobility and current vaccination strategy. Dashed lines show the impact of increasing the

423 interval between doses to 84 days for the Pfizer vaccine. Blue colors show the impact of increased vaccination rates  
424 (100,000/day) without age priority. Green colors show the impact of increased vaccination rates (100,000/day) with age priority.  
425 Gray colors show the impact of baseline vaccination rates without age priority.  
426  
427

## 428 References

- 429 1. Instituto Nacional de Salud, Colombia. Datos Coronavirus Colombia. [cited 4 Aug 2021].  
430 Available: <https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx>
- 431 2. Observatorio de Salud de Bogotá, SaluData. Casos confirmados de COVID-19 en Bogotá.  
432 [cited 4 Aug 2021]. Available: [https://saludata.saludcapital.gov.co/osb/index.php/datos-de-salud-enfermedades-trasmisibles/covid19/](https://saludata.saludcapital.gov.co/osb/index.php/datos-de-salud/enfermedades-trasmisibles/covid19/)  
433
- 434 3. Ministerio de Salud y Protección Social de Colombia. Vacunación contra COVID-19. [cited  
435 6 Aug 2021]. Available:  
436 <https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx>
- 437 4. Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, Hasell J, Macdonald B, et al.  
438 Coronavirus Pandemic (COVID-19). Our World in Data. 2020 [cited 4 Aug 2021].  
439 Available: <https://ourworldindata.org/covid-vaccinations?country=COL>
- 440 5. Observatorio de Salud de Bogotá, SaluData. COVID-19 Vacunómetro. [cited 4 Aug 2021].  
441 Available: <https://saludata.saludcapital.gov.co/osb/index.php/datos-de-salud/enfermedades-trasmisibles/covid-19-vacunometro/>  
442
- 443 6. Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA,  
444 Andrés Prada D, et al. Characterization of the emerging B.1.621 variant of interest of  
445 SARS-CoV-2. bioRxiv. medRxiv; 2021. doi:10.1101/2021.05.08.21256619
- 446 7. CoVariants. [cited 2 Jul 2021]. Available: <http://covariants.org>
- 447 8. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.  
448 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med.  
449 2021. doi:10.1056/NEJMoa2108891
- 450 9. Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2  
451 Variants and Vaccines. N Engl J Med. 2021;385: 179–186.
- 452 10. España G, Cucunubá ZM, Diaz H, Cavany S, Castañeda N, Rodriguez L. The impact of  
453 school reopening on COVID-19 dynamics in Bogotá, Colombia. 2021.  
454 doi:10.31219/osf.io/ebjx9
- 455 11. España G, Cavany S, Oidtman R, Barbera C, Costello A, Lerch A, et al. Impacts of K-12  
456 school reopening on the COVID-19 epidemic in Indiana, USA.  
457 doi:10.1101/2020.08.22.20179960
- 458 12. Moghadas SM, Vilches TN, Zhang K, Nourbakhsh S, Sah P, Fitzpatrick MC, et al.  
459 Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol.  
460 2021;19: e3001211.
- 461 13. Romero-Brufau S, Chopra A, Ryu AJ, Gel E, Raskar R, Kremers W, et al. Public health  
462 impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation

- 463 agent based modeling study. *BMJ*. 2021;373: n1087.
- 464 14. Robertson JFR, Sewell HF. COVID-19 vaccine efficacy data: solid enough to delay second  
465 dose? *The Lancet*. 2021. pp. 2248–2249.
- 466 15. Iacobucci G, Mahase E. Covid-19 vaccination: What’s the evidence for extending the  
467 dosing interval? *BMJ*. 2021;372: n18.
- 468 16. Ledford H. Delaying a COVID vaccine’s second dose boosts immune response. *Nature*.  
469 2021. doi:10.1038/d41586-021-01299-y
- 470 17. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.  
471 Single-dose administration and the influence of the timing of the booster dose on  
472 immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis  
473 of four randomised trials. *Lancet*. 2021;397: 881–891.
- 474 18. Departamento Administrativo Nacional de Estadísticas, DANE. Encuesta Pulso Social.  
475 [cited 7 Aug 2021]. Available: [https://www.dane.gov.co/index.php/estadisticas-por-](https://www.dane.gov.co/index.php/estadisticas-por-tema/encuesta-pulso-social)  
476 [tema/encuesta-pulso-social](https://www.dane.gov.co/index.php/estadisticas-por-tema/encuesta-pulso-social)
- 477 19. Instituto Nacional de Salud, Colombia. Datos Coronavirus Colombia. In:  
478 <https://www.ins.gov.co/Noticias/paginas/coronavirus.aspx> [Internet]. [cited 7 Aug 2021].  
479 Available: <https://www.ins.gov.co/Noticias/paginas/coronavirus.aspx>
- 480 20. Mercado-Reyes M, Malagón-Rojas JN, Zapata S, Rodríguez-Barraquer I, Toloza-Pérez YG,  
481 Wiesner M, et al. Seroprevalence of Anti-Sars-Cov-2 Antibodies in Colombia, 2020: A  
482 Population-Based Study. SSRN. 2021. Available: <https://papers.ssrn.com/abstract=3890833>
- 483 21. GISAID - Initiative. [cited 2 Aug 2021]. Available: <https://www.gisaid.org/>
- 484 22. Google. COVID-19 Community Mobility Reports. Available:  
485 <https://www.google.com/covid19/mobility/>
- 486 23. UNDP. Impacto de las Políticas de Aislamiento a partir del COVID 19. [cited 5 Aug 2021].  
487 Available: <https://covid.grandata.com>
- 488 24. Ministerio de Salud y Protección Social, Colombia. Tablero de vacunación COVID-19  
489 Colombia. [cited 7 Aug 2021]. Available: [https://drive.google.com/file/d/1N4V-](https://drive.google.com/file/d/1N4V-qqp6q8exuYAZgZ79GT9GazsSCHUK/edit)  
490 [qqp6q8exuYAZgZ79GT9GazsSCHUK/edit](https://drive.google.com/file/d/1N4V-qqp6q8exuYAZgZ79GT9GazsSCHUK/edit)
- 491 25. De Castro Ramos FJ. Proyecciones de población. [cited 6 Aug 2021]. Available:  
492 [https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-](https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion)  
493 [poblacion/proyecciones-de-poblacion](https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion)
- 494 26. IPUMS (Integrated Public Use Microdata Series). [cited 5 Aug 2021].  
495 doi:10.4135/9781452225272.n94
- 496 27. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2 B.1.617.2

- 497 Delta variant emergence, replication and sensitivity to neutralising antibodies. bioRxiv.  
498 2021. p. 2021.05.08.443253. doi:10.1101/2021.05.08.443253
- 499 28. CoVariants. [cited 4 Aug 2021]. Available: <http://Covariants.org>
- 500 29. SARS-CoV-2 Variants of Concern and Variants Under Investigation in England: Technical  
501 briefing 7. Public Health England; 2021.
- 502 30. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido D da S, Mishra S, et al. Genomics  
503 and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science*. 2021;372:  
504 815–821.
- 505 31. SAGE SPI-M-O. SPI-M-O: Summary of further modelling of easing restrictions – Roadmap  
506 Step 2. In:  
507 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/975909/S1182\\_SPI-M-](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975909/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf)  
508 [O\\_Summary\\_of\\_modelling\\_of\\_easing\\_roadmap\\_step\\_2\\_restrictions.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975909/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf) [Internet]. 3 Jan  
509 2021. Available:  
510 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/975909/S1182\\_SPI-M-](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975909/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf)  
511 [O\\_Summary\\_of\\_modelling\\_of\\_easing\\_roadmap\\_step\\_2\\_restrictions.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975909/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf)
- 514 32. Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos J do P, Tilli Reis Pessoa  
515 Conde M, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare  
516 Professionals in Brazil: The PROFISCOV Study. SSRN. 2021. doi:10.2139/ssrn.3822780
- 517 33. Ministerio de Salud, Gobierno de Chile. Efectividad de la vacuna CoronaVac con virus  
518 inactivo contra SARS-CoV-2 en Chile. [cited 6 Aug 2021]. Available:  
519 [https://www.minsal.cl/wp-content/uploads/2021/04/20210416\\_ESTUDIO-EFECTIVIDAD-](https://www.minsal.cl/wp-content/uploads/2021/04/20210416_ESTUDIO-EFECTIVIDAD-CORONAVAC.pdf)  
520 [CORONAVAC.pdf](https://www.minsal.cl/wp-content/uploads/2021/04/20210416_ESTUDIO-EFECTIVIDAD-CORONAVAC.pdf)
- 521 34. Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Six month  
522 safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. bioRxiv. medRxiv; 2021.  
523 doi:10.1101/2021.07.28.21261159
- 524 35. BioNTech PA. Pfizer and BioNTech Confirm High Efficacy and No Serious Safety  
525 Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis  
526 of Landmark COVID-19 Vaccine Study. [cited 5 Aug 2021]. Available:  
527 [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious)  
528 [confirm-high-efficacy-and-no-serious](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious)
- 529 36. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety  
530 of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384: 403–416.
- 531 37. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and  
532 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*.  
533 2021;384: 2187–2201.

- 534 38. Stowe J, Andrews N, Gower G, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of  
535 COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. [cited 6  
536 Aug 2021]. Available: [https://khub.net/web/phe-national/public-library/-  
537 /document\\_library/v2WsRK3ZIEig/view\\_file/479607329?\\_com\\_liferay\\_document\\_library\\_  
538 web\\_portlet\\_DLPortlet\\_INSTANCE\\_v2WsRK3ZIEig\\_redirect=https%3A%2F%2Fkhub.ne  
539 t%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-  
540 %2Fdocument\\_library%2Fv2WsRK3ZIEig%2Fview%2F479607266](https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZIEig/view_file/479607329?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZIEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZIEig%2Fview%2F479607266)
- 541 39. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing  
542 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2  
543 infection. *Nat Med.* 2021;27: 1205–1211.
- 544 40. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody  
545 activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.  
546 *Lancet.* 2021;397: 2331–2333.

547